The term “bifunctional molecules” covers a collection of related modalities with different but similar strategies. They are opening up once-inaccessible targets and enabling the development of drugs that are less susceptible to target protein mutations. However, as with any new modality, they face challenges and continue to benefit from new tools. In this paper from WuXi Apptec and Scrip, you can learn more including the tools that enable bifunctional R&D, and the future of the field.
Read the full article here.
